(Q30365939)

21 June 2017

1 reference

title

The entero-insular axis: implications for human metabolism. (English)

1 reference

21 June 2017

Lakshminarayan R Ranganath

series ordinal

1

1 reference

21 June 2017

1 January 2008

1 reference

Clinical Chemistry and Laboratory Medicine

21 June 2017

1 reference

21 June 2017

46

1 reference

21 June 2017

1

1 reference

21 June 2017

43-56

1 reference

Hamster preproglucagon contains the sequence of glucagon and two related peptides.

21 June 2017

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Conflicting gastric inhibitory polypeptide data: possible causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

The effect of circulating non-esterified fatty acids on the entero-insular axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: protein kinase A-dependent endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Involvement of the ryanodine-sensitive Ca2+ store in GLP-1-induced Ca2+ oscillations in insulin-secreting HIT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

The development of beta-cell mass: recent progress and potential role of GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucose-dependent insulinotropic polypeptide as a regulator of beta cell function and fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and dow

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Attenuated GLP-1 secretion in obesity: cause or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF- Inhibitors, and GLP-1 Receptor Agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Mechanism of circadian variation in bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Role of gastrointestinal hormones in postprandial reduction of bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Effect of Intermittent Endogenous Hyperglucagonemia on Glucose Homeostasis in Normal and Diabetic Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Glucagon and the A cell: physiology and pathophysiology (first two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Insulin treatment and the problem of weight gain in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Stability of body weight in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Role and integration of mechanisms controlling gastric emptying

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Studies of pancreatic alpha cell function in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Nuclear protein p8 is associated with glucose-induced pancreatic beta-cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.008

21 January 2018

Identifiers

DOI

10.1515/CCLM.2008.008

1 reference

21 June 2017

1 reference

PubMed ID

18020966